West Paces Advisors
RVMD icon

West Paces Advisors’s Revolution Medicines RVMD Stock Holding History

West Paces Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2
Closed -$375 – 774
2026
Q2 		$375 Buy
+2
New +$292 ﹤0.01% 716

Other funds holding RVMD

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Mass General Brigham
Mass General Brigham Somerville, Massachusetts $456M AUM 27.51% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return
Loftus Peak
Loftus Peak Sydney, Australia $781M AUM
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

West Paces Advisors's RVMD Position: Q3 2026 in Review

West Paces Advisors sold out of Revolution Medicines (RVMD) in Q3 2026, closing a stake of 2 shares — an estimated $375 sold.

West Paces Advisors first reported a position in RVMD in Q2 2026 and held it in 1 quarter. The position peaked at $375 in Q2 2026. 269 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • West Paces Advisors reported no remaining Revolution Medicines position as of Q3 2026 after selling out during the quarter.
  • West Paces Advisors sold 2 Revolution Medicines shares in Q3 2026, an estimated $375.
  • West Paces Advisors first reported a position in Revolution Medicines in Q2 2026 and held it in 1 quarter.
  • West Paces Advisors's Revolution Medicines position peaked at $375 in Q2 2026.
  • 269 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on West Paces Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.